Victims who experienced hearing loss (or other hearing problems) after receiving IV infusions of TEPEZZA®—the first-ever FDA-approved drug for thyroid eye disease (TED)---should pay attention to this crucial information.

TEPEZZA® (also known as Teprotumumab) has been found in numerous studies to be linked with severe hearing complications, including:

• Hearing loss (hyperacusis)
• Tinnitus (ringing in the ears)
• Sensations of ears being "plugged" or "full"
• Autophony (an enhanced perception of one's bodily sounds, especially voice and breathing)

TEPEZZA® has shown to be an effective drug for treating Thyroid Eye Disease (TED), typically caused by Grave's disease.

However, the manufacturer may need to adequately warn patients and their doctors about the severity of hearing-related risks.

Some studies reported that as much as 65% of patients who received TEPEZZA® infusions suffered hearing-related side effects—many of which appear irreversible.

The manufacturer of TEPEZZA®, Horizon Therapeutics, reported in their pre-market and post-market clinical trials that only 10% of those who received TEPEZZA® reported hearing complications—which happens to be far less than what many other recent studies show.

Also, the manufacturer reported that the hearing-related side effects reported in their clinical trials were mainly "temporary."

In contrast, other studies have reported that hearing-related side effects persisted even after discontinuation of TEPEZZA®—and may be permanent.

For many patients suffering from thyroid eye disease (TED), the reported 10% rate of temporary hearing problems during treatments was well worth the risk.

However, numerous published studies have come to light, showing that hearing-related risks could be as high as 65% in patients.

Those who suffer permanent hearing loss or tinnitus due to TEPEZZA® infusions may incur astronomical healthcare costs for the remainder of their life.

Health insurance companies are already trying to limit their liability and coverages for these new, advanced hearing tests and hearing aids due to their ever-increasing costs.

There is a tiny window of time for victims to seek financial compensation after an injury, and the time window for pursuing a case differs in each state.

An Update to the TEPEZZA® and Thyroid Eye Disease Treatment

The US FDA has given the green light for Horizon Therapeutics’ TEPEZZA® (teprotumumab-trbw) label to include new information about treating thyroid eye disease (TED) patients, no matter how long they have had the disease or how active it is.

TEPEZZA®, an insulin-like growth factor-1 receptor inhibitor, is the first and only medicine FDA-approved for TED. This rare autoimmune disease can worsen over time, affecting vision and causing debilitation.

Horizon Therapeutics' CEO, Tim Walbert, shared, “We collaborated closely with the FDA for this important label update, showing how TEPEZZA® can help people with thyroid eye disease, regardless of how active or long-lasting their condition is."

Previously, TEPEZZA® was already approved for treating thyroid eye disease, but this new label update emphasizes its use for all patients dealing with the full range of the disease's effects.

We believe that victims who suffered hearing problems after taking TEPEZZA® for thyroid eye disease should receive justice and compensation for losses.